- Company
- Lilly appoints Stacie Liu to head the CardioMetabolic Health
- by Eo, Yun-Ho Nov 28, 2024 05:54am
- Lilly Korea has named Stacie Liu (37), as the new Senior Director of its CardioMetabolic Health Business Unit On the 1st, Lilly Korea announced that it had appointed Stacie Liu as the Senior Director of its CardioMetabolic Health Business Unit. In this role, Liu will be responsible for setting and executing the business strategy for Li
- Company
- ‘The new ATTR-CM treatment can improve patient survival’
- by Whang, byung-woo Nov 27, 2024 05:50am
- With the possibility for reimbursement coverage for the ultra-rare disease,&160;transthyretin amyloid cardiomyopathy (ATTR-CM) rising, excitement is also rising in the clinical site. Due to the short life expectancy of ATTR-CM - 2-3.5 years after diagnosis &8211; and no clear treatment option available, the benefits of a new treatment optio
- Company
- Active development of new drugs for myasthenia gravis
- by Son, Hyung Min Nov 27, 2024 05:50am
- Competition in the pharmaceutical market is heating up to secure myasthenia gravis indication. UCB's new drug was approved in South Korea, and Janssen finished the phase 3 trial, aiming to acquire regulatory approvals worldwide. In South Korea, Handok seeks to enter the market with its acquired new drug. HanAll Biopharma is conducting a Phase 3
- Company
- 4 of 5 listed pharma companies expand investments
- by Chon, Seung-Hyun Nov 26, 2024 05:54am
- Pharmaceutical companies have significantly expanded their research and development (R&D) investments to discover their next item. Five out of five major pharma and biotech companies increased their R&D spending this year compared to the previous year. The top pharmaceutical companies in terms of sales have been investing heavily in R&D to devel
- Company
- Will Imfinzi and Imjudo be reimbursed in Korea?
- by Eo, Yun-Ho Nov 26, 2024 05:54am
- Whether the immuno-oncology drug combination of Imfinzi and Imjudo will gain a place as a treatment option for liver cancer in Korea is gaining attention. AstraZeneca Korea's combination therapy of PD-L1 inhibitor Imfinzi (durvalumab) and CTLA-4 inhibitor Imjudo (tremelimumab) recently passed the Health Insurance Review and Assessment S
- Company
- ‘Oral drugs can address the unmet PNH treatment needs’
- by Son, Hyung Min Nov 26, 2024 05:54am
- The paroxysmal nocturnal hemoglobinuria (PNH) market, which has been dominated by AstraZeneca's Soliris and Ultomiris, has seen the introduction of the oral drug Fabhalta. Experts believe that Fabhalta’s use will increase in the future as it has been shown to reduce anemia and blood transfusions compared to existing treatments.&160; On
- Company
- "Pharmaceutical companies using CSOs must renew contracts
- by Kim, Jin-Gu Nov 26, 2024 05:53am
- Based on the Contract Sales Organization (CSO) reporting system implemented last month, pharmaceutical companies must be aware of potential legal risks. Pharmaceutical companies using CSOs must sign contracts with companies that have completed registration and renew existing contracts to align with the timeline following reporting. On Nove
- Company
- K-Bio to showcase at the ASH 2024
- by Son, Hyung Min Nov 25, 2024 05:54am
- Development accomplishments of the Korean pharmaceutical industry's blood cancer treatments will be showcased at an international conference. Hanmi Pharmaceutical, PharosiBio, LigaChem Biosciences, and Aptamer Sciences will present their promising clinical study results, and they are set to join the global stage. PharosiBio and Hanmi P
- Company
- 'Altuviiio' for hemophilia A expected to be marketed in KOR
- by Eo, Yun-Ho Nov 25, 2024 05:53am
- 'Altuviiio,' a new once-weekly administered hemophilia A drug, is expected to be marketed in South Korea. According to industry sources, Sanofi-Aventis has recently submitted an application for approval of Altuviiio (efanesoctocog alfa). The Ministry of Food and Drug Safety (MFDS) granted this drug an Orphan Drug Designation (ODD) in M
- Company
- "Korean pharma draws attention, open innovation will heat up
- by Son, Hyung Min Nov 22, 2024 05:56am
- Global pharmaceutical companies continue to invest in research & development (R&D) to overcome patent expiration. Industry experts have said that open innovation between global pharmaceutical companies and Korean pharmaceutical companies will be fired up, enabling collaborations in various diseases. According to industry sources on Novem
